PMID- 35207637
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220322
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Electronic)
IS  - 2075-4426 (Linking)
VI  - 12
IP  - 2
DP  - 2022 Jan 24
TI  - Microphysiological Neurovascular Barriers to Model the Inner Retinal 
      Microvasculature.
LID - 10.3390/jpm12020148 [doi]
LID - 148
AB  - Blood-neural barriers regulate nutrient supply to neuronal tissues and prevent 
      neurotoxicity. In particular, the inner blood-retinal barrier (iBRB) and 
      blood-brain barrier (BBB) share common origins in development, and similar 
      morphology and function in adult tissue, while barrier breakdown and leakage of 
      neurotoxic molecules can be accompanied by neurodegeneration. Therefore, 
      pre-clinical research requires human in vitro models that elucidate 
      pathophysiological mechanisms and support drug discovery, to add to animal in 
      vivo modeling that poorly predict patient responses. Advanced cellular models 
      such as microphysiological systems (MPS) recapitulate tissue organization and 
      function in many organ-specific contexts, providing physiological relevance, 
      potential for customization to different population groups, and scalability for 
      drug screening purposes. While human-based MPS have been developed for tissues 
      such as lung, gut, brain and tumors, few comprehensive models exist for ocular 
      tissues and iBRB modeling. Recent BBB in vitro models using human cells of the 
      neurovascular unit (NVU) showed physiological morphology and permeability values, 
      and reproduced brain neurological disorder phenotypes that could be applicable to 
      modeling the iBRB. Here, we describe similarities between iBRB and BBB 
      properties, compare existing neurovascular barrier models, propose leverage of 
      MPS-based strategies to develop new iBRB models, and explore potentials to 
      personalize cellular inputs and improve pre-clinical testing.
FAU - Maurissen, Thomas L
AU  - Maurissen TL
AUID- ORCID: 0000-0002-9686-2400
AD  - Roche Pharma Research and Early Development, Immunology, Infectious Diseases and 
      Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 
      Grenzacherstrasse 124, 4070 Basel, Switzerland.
FAU - Pavlou, Georgios
AU  - Pavlou G
AD  - Department of Biological Engineering, Massachusetts Institute of Technology, 77 
      Massachusetts Ave., MIT Building, Room NE47-321, Cambridge, MA 02139, USA.
FAU - Bichsel, Colette
AU  - Bichsel C
AUID- ORCID: 0000-0001-7468-3025
AD  - Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche 
      Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 
      Basel, Switzerland.
AD  - Roche Pharma Research and Early Development, Institute for Translational 
      Bioengineering, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 
      Grenzacherstrasse 124, 4070 Basel, Switzerland.
FAU - Villasenor, Roberto
AU  - Villasenor R
AD  - Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, 
      Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 
      4070 Basel, Switzerland.
FAU - Kamm, Roger D
AU  - Kamm RD
AUID- ORCID: 0000-0002-7232-304X
AD  - Department of Biological Engineering, Massachusetts Institute of Technology, 77 
      Massachusetts Ave., MIT Building, Room NE47-321, Cambridge, MA 02139, USA.
AD  - Department of Mechanical Engineering, Massachusetts Institute of Technology, 77 
      Massachusetts Ave., MIT Building, Room NE47-321, Cambridge, MA 02139, USA.
FAU - Ragelle, Heloise
AU  - Ragelle H
AUID- ORCID: 0000-0003-0650-9601
AD  - Roche Pharma Research and Early Development, Immunology, Infectious Diseases and 
      Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 
      Grenzacherstrasse 124, 4070 Basel, Switzerland.
LA  - eng
GR  - R01 NS121078/NS/NINDS NIH HHS/United States
GR  - RPF-ID:565/Roche Postdoctoral Fellowship/
GR  - R01 NS121078 and R21 NS105027/NIH National Institute for Neurological Disorders 
      and Stroke/
PT  - Journal Article
PT  - Review
DEP - 20220124
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC8876566
OTO - NOTNLM
OT  - 3D models
OT  - blood-neural barriers
OT  - disease modeling
OT  - inner blood-retinal barrier
OT  - microphysiological systems
OT  - neurovascular unit
OT  - organ-on-a-chip
COIS- T.L.M., C.B., R.V. and H.R. are employees of F. Hoffmann-La Roche Ltd. R.K. is 
      co-founder of AIM Biotech, and receives research support from F. Hoffmann-La 
      Roche Ltd., AbbVie, Amgen, Glaxo-Smith-Kline, Novartis, and Boehringer Ingelheim.
EDAT- 2022/02/26 06:00
MHDA- 2022/02/26 06:01
PMCR- 2022/01/24
CRDT- 2022/02/25 01:12
PHST- 2021/12/15 00:00 [received]
PHST- 2022/01/14 00:00 [revised]
PHST- 2022/01/18 00:00 [accepted]
PHST- 2022/02/25 01:12 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/02/26 06:01 [medline]
PHST- 2022/01/24 00:00 [pmc-release]
AID - jpm12020148 [pii]
AID - jpm-12-00148 [pii]
AID - 10.3390/jpm12020148 [doi]
PST - epublish
SO  - J Pers Med. 2022 Jan 24;12(2):148. doi: 10.3390/jpm12020148.